Pharmacotherapeutic aspects of treating knee osteoarthritis with glucosamine sulfate
Steven Simoens, Gert Laekeman
.
DOI: 10.4236/health.2010.27107   PDF   HTML     5,446 Downloads   9,889 Views   Citations

Abstract

Glucosamine sulfate is a natural constituent of cartilage and is used in the treatment of knee osteoarthritis. The aim of this study is to provide a short but comprehensive pharmacotherapeutic update on treating knee osteoarthritis with glucosamine sulfate. A literature search was conducted of PubMed, Centre for Reviews and Dissemination databases, Cochrane Reviews and EconLit up to January 2010. The literature review indicated that the mechanism of action of glucosamine sulfate is based on hypothesis, but its treatment effects in knee osteoarthritis are symptomatic. With steady-state peak concentrations at the 1,500 mg dosage in the range of 10 µM, it is estimated that only 2% of glucosamine is incorporated in the cartilage. A once-daily dosage of 1,500 mg of glucosamine sulfate is licensed for the treatment of symptomatic osteoarthritis and has been shown to reduce pain, improve function and exhibit similar safety to placebo. Glucosamine sulfate is likely to be a cost-effective treatment of knee osteoarthritis. In conclusion, a once-daily dosage of 1,500 mg of glucosamine sulfate is likely to be a safe, effective and cost-effective treatment of knee osteoarthritis as compared to placebo.

Share and Cite:

Simoens, S. and Laekeman, G. (2010) Pharmacotherapeutic aspects of treating knee osteoarthritis with glucosamine sulfate. Health, 2, 705-707. doi: 10.4236/health.2010.27107.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Towheed, T., Maxwell, L., Anastassiades, T.P., Shea, B., Houpt, J.B., Welch, V., Hochberg, M.C. and Wells, G.A. (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews, 2.
[2] Setnikar, I. and Rovati, L.C. (2001) Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung, 51(9), 699-725.
[3] Persiani, S., Roda, E., Rovati, L.C., Locatelli, M., Giacovelli, G. and Roda, A. (2005) Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis and Cartilage, 13(12), 1041-1049.
[4] Persiani, S., Rotini, R., Trisolino, G., Rovati, L.C., Locatelli, M., Paganini, D., Antonioli, D. and Roda, A. (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis and Cartilage, 15(7), 764-772.
[5] Simoens, S. (2009) Economic evaluation of glucosamine sulphate treatment in knee osteoarthritis. ISPOR’s 12th Annual European Congress, 24-27 October, Paris.
[6] National Institute for Health and Clinical Excellence. (2009) Osteoarthritis: The care and management of osteoarthritis in adults: NICE clinical guideline 59. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf
[7] Ku, L.J.E. and Biddle, A. (2009) Cost-effectiveness of glucosamine sulfate treatment among elderly knee osteoarthritis patients. 7th World IHEA Congress on Health Economics, Beijing.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.